COMMUNIQUÉS West-GlobeNewswire

PharmAla Issues Q3 Financial Statements and AGM Update
30/07/2026
TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
30/07/2026
Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA) FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support [...]
Immutep Quarterly Activities Report Q4 FY26
30/07/2026
Media Release Pooled analysis of five efti trials (presented at ASCO 2026) reinforced efti's mechanism of action, tying immune activation to a 7.7-month median overall survival benefit in biological responders across [...]
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
30/07/2026
MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
30/07/2026
Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of [...]
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
30/07/2026
MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
30/07/2026
Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company [...]
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
30/07/2026
Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time; Registration Is [...]
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
30/07/2026
Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also inform WVE-007's potential in [...]
NewGen Provides Update on K25.ai Investment and Strengthened Financial Position
30/07/2026
NewGen’s total shares outstanding count expected to reach 5.9 million following recently announced share issuance, bolstering market capitalization NewGen’s agreed 13% stake in K25.ai is now valued at approximately US$ [...]
MMI Receives FDA Approval to Advance to Phase II of Patient Enrollment in Groundbreaking REMIND Microsurgical Study in Alzheimer’s Patients
30/07/2026
FDA-approved supplement advances early feasibility study (EFS) toward full enrollment JACKSONVILLE, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- MMI (Medical Microinstruments, Inc.), a robotics company dedicated to [...]
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
30/07/2026
Company to report second quarter 2026 financial results on August 6 SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of [...]
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
30/07/2026
Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate’s Precision Timed Release™ platform technology KANSAS CITY, Kan., July 30, 2026 (GLOBE NEWSWIRE) -- [...]
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
30/07/2026
Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential to accelerate patient access to effective therapies for [...]
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
30/07/2026
STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling More than 70% of patients do not [...]
Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share
30/07/2026
Lite Strategy Buys Back Roughly 4.9 Million Shares at an Average Price of $1.11 with No Debt Incurred SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), [...]
Glow Peptide Stack Launched by Kylo Peptides for Laboratory Use
30/07/2026
Sheridan, Wyoming , July 30, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides has announced that it has added the GLOW peptide stack to its research catalog. The product supplies three separately sealed, lyophilized vials of the [...]
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
30/07/2026
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of [...]
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
30/07/2026
Completion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate Development MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or [...]

Pages